Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: In vitro and clinical studies

Clinical Pharmacology and Therapeutics

Volumn 79, Issue 1, 2006, Pages 125-133

  Greenblatt, David J ^a   Von Moltke, Lisa L ^a   Perloff, Elke Störmer ^a   Luo, Yan ^a   Harmatz, Jerold S ^a   Zinny, Miguel A ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C9; FLUCONAZOLE; FLURBIPROFEN; SULFAPHENAZOLE; WARFARIN;

ANTICOAGULATION; ARTICLE; BIOTRANSFORMATION; CONTROLLED STUDY; CRANBERRY JUICE; DATA ANALYSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HYDROXYLATION; DRUG POTENTIATION; ENANTIOMER; ENZYME ACTIVITY; ENZYME INHIBITION; GRAPE JUICE; HALF LIFE TIME; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; NORMAL HUMAN; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TEA;

ADULT; ALGORITHMS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIFUNGAL AGENTS; AREA UNDER CURVE; BEVERAGES; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; FLUCONAZOLE; FLURBIPROFEN; FOOD-DRUG INTERACTIONS; HALF-LIFE; HUMANS; MALE; MICROSOMES, LIVER; TEA; VACCINIUM MACROCARPON; VITIS;

EID: 30444445695     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2005.09.014     Document Type: Article

References (60)

1. D.G. Bailey, J.M.O. Arnold, J.D. Spence Grapefruit juice-drug interactions Br J Clin Pharmacol 46 1998 101 110
2. G.C. Kane, J.J. Lipsky Drug-grapefruit juice interactions Mayo Clin Proc 75 2000 933 942
3. B. Ameer, R.A. Weintraub Drug interactions with grapefruit juice Clin Pharmacokinet 33 1997 103 121
4. U. Fuhr Drug interactions with grapefruit juice. Extent, probable mechanism and clinical relevance Drug Saf 18 1998 251 272
5. D.J. Greenblatt, K.C. Patki, L.L. von Moltke, R.I. Shader Drug interactions with grapefruit juice an update J Clin Psychopharmacol 21 2001 357 359
6. D.J. Greenblatt, L.L. von Moltke, J.S. Harmatz, G. Chen, J.L. Weemhoff, C. Jen Time-course of recovery of CYP3A function after single doses of grapefruit juice Clin Pharmacol Ther 74 2003 121 129
7. R. Suvarna, M. Pirmohamed, L. Henderson Possible interaction between warfarin and cranberry juice BMJ 327 2003 1454
8. P. Grant Warfarin and cranberry juice an interaction? J Heart Valve Dis 13 2004 25 26
9. H. Yamazaki, T. Shimada Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R- and S-warfarin enantiomers Biochem Pharmacol 54 1997 1195 1203
10. M. He, K.L. Kunze, W.F. Traeger Inhibition of (S)-warfarin metabolism by sulfinpyrazone and its metabolites Drug Metab Dispos 23 1995 659 663
11. D.J. Greenblatt, L.L. von Moltke Interaction of warfarin with drugs, natural substances, and foods J Clin Pharmacol 45 2005 127 132
12. Committee on Safety of Medicines, Medicines and Healthcare Products Regulatory Agency Interaction between warfarin and cranberry juice new advice Curr Probl Pharmacovigil 30 2004 10
13. J.O. Miners, D.J. Birkett Cytochrome P4502C9 an enzyme of major importance in human drug metabolism Br J Clin Pharmacol 45 1998 525 538
14. A.E. Rettie, J.P. Jones Clinical and toxicological relevance of CYP2C9 drug-drug interactions and pharmacogenetics Annu Rev Pharmacol Toxicol 45 2005 477 494
15. J.A. Goldstein, S.M.F. de Morais Biochemistry and molecular biology of the human CYP2C subfamily Pharmacogenetics 4 1994 285 299
16. C.R. Bhasker, J.O. Miners, S. Coulter, D.J. Birkett Allelic and functional variability of cytochrome P4502C9 Pharmacogenetics 7 1997 51 58
17. M.J. Stubbins, L.W. Harries, G. Smith, M.H. Tarbit, C.R. Wolf Genetic analysis of the human cytochrome P450 CYP2C9 locus Pharmacogenetics 6 1996 429 439
18. K. Inoue, H. Yamazaki, K. Imiya, S. Akasaka, F.P. Guengerich, T. Shimada Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations Pharmacogenetics 7 1997 103 113
19. A. Odani, Y. Hashimoto, Y. Otsuki, Y. Uwai, H. Hattori, K. Furusho Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy Clin Pharmacol Ther 62 1997 287 292
20. H.G. Xie, H.C. Prasad, R.B. Kim, C.M. Stein CYP2C9 allelic variants ethnic distribution and functional significance Adv Drug Deliv Rev 54 2002 1257 1270
21. C.R. Lee, J.A. Goldstein, J.A. Pieper Cytochrome P450 2C9 polymorphisms a comprehensive review of the in-vitro and human data Pharmacogenetics 12 2002 251 263
22. G.P. Aithal, C.P. Day, P.J. Kesteven, A.K. Daly Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications Lancet 353 1999 717 719
23. K. Venkatakrishnan, L.L. von Moltke, D.J. Greenblatt Human drug metabolism and the cytochromes P450 application and relevance of in vitro models J Clin Pharmacol 41 2001 1149 1179
24. X. Jiang, K.M. Williams, W.S. Liauw, A.J. Ammit, B.D. Roufogalis, C.C. Duke Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects Br J Clin Pharmacol 59 2005 425 432
25. T.S. Tracy, C. Marra, S.A. Wrighton, F.J. Gonzalez, K.R. Korzekwa Studies of flurbiprofen 4'-hydroxylation. Additional evidence suggesting the sole involvement of cytochrome P450 2C9 Biochem Pharmacol 52 1996 1305 1309
26. N.M. Davies Clinical pharmacokinetics of flurbiprofen and its enantiomers Clin Pharmacokinet 28 1995 100 114
27. G.M. Giancarlo, K. Venkatakrishnan, B.W. Granda, L.L. von Moltke, D.J. Greenblatt Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro inhibition by sulfaphenazole, omeprazole and ticlopidine Eur J Clin Pharmacol 57 2001 31 36
28. R.F. Frye, T.S. Tracy, J.M. Hutzler, K.R. Korzekwa, Y. Cannon, M. Pauli Flurbiprofen as a selective in vivo probe of CYP2C9 activity [abstract] Clin Pharmacol Ther 67 2000 109
29. C.R. Lee, J.A. Pieper, R.F. Frye, A.L. Hinderliter, J.A. Blaisdell, J.A. Goldstein Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans J Clin Pharmacol 43 2003 84 91
30. C.R. Lee, J.A. Pieper, R.F. Frye, A.L. Hinderliter, J.A. Blaisdell, J.A. Goldstein Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes Eur J Clin Pharmacol 58 2003 791 794
31. B.K. Patel, S.H. Jackson, C.G. Swift, A.J. Hutt Disposition of flurbiprofen in man influence of stereochemistry and age Xenobiotica 33 2003 1043 1057
32. H. Yamazaki, T. Shimada Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin Drug Metab Dispos 26 1998 1053 1057
33. L.L. von Moltke, D.J. Greenblatt, J.S. Harmatz, R.I. Shader Alprazolam metabolism in vitro studies of human, monkey, mouse, and rat liver microsomes Pharmacology 47 1993 268 276
34. L.L. von Moltke, D.J. Greenblatt, J.M. Grassi, B.W. Granda, K. Venkatakrishnan, S.X. Duan Citalopram and desmethylcitalopram in vitro human cytochromes mediating transformation, and cytochrome inhibitory effects Biol Psychiatry 46 1999 839 849
35. L.L. von Moltke, D.J. Greenblatt, M.H. Court, S.X. Duan, J.S. Harmatz, R.I. Shader Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine comparison with other selective serotonin reuptake inhibitor antidepressants J Clin Psychopharmacol 15 1995 125 131
36. K. Venkatakrishnan, L.L. von Moltke, D.J. Greenblatt Effects of the antifungal agents on oxidative drug metabolism in humans clinical relevance Clin Pharmacokinet 38 2000 111 180
37. D. Debruyne, J.P. Ryckelynck Clinical pharmacokinetics of fluconazole Clin Pharmacokinet 24 1993 10 27
38. D.J. Greenblatt, L.L. von Moltke, J.S. Harmatz, P. Mertzanis, J.A. Graf, A.L.B. Durol Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole Clin Pharmacol Ther 64 1998 661 671
39. J. Reed Cranberry flavonoids, atherosclerosis and cardiovascular health Crit Rev Food Sci Nutr 42 2002 301 316
40. J.E. Freedman, C. Parker III, L. Li, J.A. Perlman, B. Frei, V. Ivanov Select flavonoids and whole juice from purple grapes inhibit platelet function and enhance nitric oxide release Circulation 103 2001 2792 2798
41. J.G. Keevil, H.E. Osman, J.D. Reed, J.D. Folts Grape juice, but not orange juice or grapefruit juice, inhibits human platelet aggregation J Nutr 130 2000 53 56
42. K.L. Kunze, L.C. Wienkers, K.E. Thummel, W.F. Trager Warfarin- fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies Drug Metab Dispos 24 1996 414 421
43. D.J. Black, K.L. Kunze, L.C. Wienkers, B.E. Gidal, T.L. Seaton, N.D. McDonnell Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies Drug Metab Dispos 24 1996 422 428
44. K.L. Kunze, W.F. Trager Warfarin-fluconazole. III. A rational approach to management of a metabolically based drug interaction Drug Metab Dispos 24 1996 429 435
45. J.M. Neal, K.L. Kunze, R.H. Levy, R.A. O'Reilly, W.F. Trager Kiiv, an in vivo parameter for predicting the magnitude of a drug interaction arising from competitive enzyme inhibition Drug Metab Dispos 31 2003 1043 1048
46. J.H. Lin, A.Y. Lu Inhibition and induction of cytochrome P450 and the clinical implications Clin Pharmacokinet 35 1998 361 390
47. O. Pelkonen, J. Mäenpää, P. Taavitsainen, A. Rautio, H. Raunio Inhibition and induction of human cytochrome P450 (CYP) enzymes Xenobiotica 28 1998 1203 1253
48. J.H. Lin Sense and nonsense in the prediction of drug-drug interactions Curr Drug Metab 1 2000 305 331
49. K. Ito, T. Iwatsubo, S. Kanamitsu, K. Ueda, H. Suzuki, Y. Sugiyama Prediction of pharmacokinetic alterations caused by drug-drug interactions metabolic interaction in the liver Pharmacol Rev 50 1998 387 412
50. R.J. Bertz, G.R. Granneman Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions Clin Pharmacokinet 32 1997 210 258
51. L.L. von Moltke, D.J. Greenblatt, J. Schmider, C.E. Wright, J.S. Harmatz, R.I. Shader In vitro approaches to predicting drug interactions in vivo Biochem Pharmacol 55 1998 113 122
52. K. Venkatakrishnan, L.L. von Moltke, R.S. Obach, D.J. Greenblatt Drug metabolism and drug interactions application and clinical value of in vitro models Curr Drug Metab 4 2003 423 459
53. B. Ameer, R.A. Weintraub, J.V. Johnson, R.A. Yost, R.L. Rouseff Flavanone absorption after naringin, hesperidin, and citrus administration Clin Pharmacol Ther 60 1996 34 40
54. A. Scalbert, G. Williamson Dietary intake and bioavailability of polyphenols J Nutr 130 2000 2073S 2085S
55. C. Manach, J.L. Donovan Pharmacokinetics and metabolism of dietary flavonoids in humans Free Radic Res 38 2004 771 785
56. C. Manach, A. Scalbert, C. Morand, C. Rémésy, L. Jiménez Polyphenols food sources and bioavailability Am J Clin Nutr 79 2004 727 747
57. C. Manach, G. Williamson, C. Morand, A. Scalbert, C. Rémésy Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies Am J Clin Nutr 81 2005 230S 242S
58. E. Bedir, I.I. Tatli, R.A. Khan, J. Zhao, S. Takamatsu, L.A. Walker Biologically active secondary metabolites from Ginkgo biloba J Agric Food Chem 50 2002 3150 3155
59. L.L. von Moltke, J.L. Weemhoff, E. Bedir, I.A. Khan, J.S. Harmatz, P. Goldman Inhibition of human cytochromes P450 by components of Ginkgo biloba J Pharm Pharmacol 56 2004 1039 1044
60. D.J. Greenblatt, L.L. von Moltke, E.S. Perloff, Y. Luo, J.S. Harmatz, E. Bedir Effect of Ginkgo on CYP2C9 in vitro and in vivo studies [abstract] Clin Pharmacol Ther 77 2005 P48